No Data
Express News | State Council meeting: Deploy measures to deepen the reform of Pharmaceutical and medical instruments regulatory system to promote high-quality development of the pharmaceutical industry.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities
Market movements | Bullish market stimuli lift Hong Kong pharmaceutical stocks, with Genscript soaring more than 12% and wuxi bio rising nearly 5%.
① What bullish impacts does the medical insurance centralized procurement have on pharmaceutical companies? ② How do institutions view the subsequent development of pharmaceutical stocks?
Purapharm (01498.HK) changes its auditor.
purapharm (01498.HK) announced that Ernst & Young has resigned as the auditor, effective since yesterday (28th). Ernst & Young confirmed that they were unable to reach an agreement with the company on the auditor's compensation for the 2024 fiscal year. At the same time, Deloitte Touche Tohmatsu has been appointed as the new auditor to fill the temporary vacancy left by Ernst & Young's resignation, and will serve until the end of the company's next shareholder's annual general meeting.
No Data
